|
|
|
| Development Status and Trend Analysis of Mesenchymal Stem Cells Therapeutic Products |
| MAO Kai-yun, FAN Yue-lei, WANG Yue, LU Jiao, CHEN Da-ming |
| Shanghai Information Center for Life Sciences, Chinese Academy of Sciences, Shanghai 200031, China |
|
|
|
Abstract Objective:To analyze the development status and trend of Mesenchymal stem cells (MSCs) therapeutic products in the sense of product manufacturing.Methods:Based on the Cortellis database of Clarivate Analytics, analyzed the searching results utilizing quantitative analysis and comparative analysis methods.Results:Currently, 5 MSCs therapeutic products have been launched into markets, and another 9 MSCs therapeutic products are at registration phase or Phase Ⅲ clinical trial. In addition, companies such as Mesoblast and FCB have an advantages over MSCs therapeutic products in the market. And business deals related to MSCs products are increasing in recent years, including 12 deals so far, ranging from drug development, commercial license, and patent assets sales to drug R&D cooperation in early phase. Several MSCs therapeutic products are at clinical stage, and a bright prospect can be expected for Chinese MSCs therapeutic product markets.Conclusion:Although MSCs therapeutic product market still at its preliminary stage, the market potential is considerably huge since the fast-developing technologies, enormous market demand as well as the high motivation of related companies in MSCs R&D and commercialization.
|
|
Received: 15 April 2017
Published: 25 October 2017
|
|
|
|
|
| [1] |
秦彤,苗向阳.iPS细胞研究的新进展及应用.遗传,2010,32(12):1205-1214. Qin T,Miao X Y. New development and application of ips cell. Heredity,2010,32(12):1205-1214.
|
|
|
| [2] |
Friedenstein A J, Petrakova K V, Kurolesova A I, et al. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation, 1968,6(2):230-247.
|
|
|
| [3] |
Friedenstein A J,Petrakova K V,Kurolesova A I. et al. Heterotopic of bone marrow. Analysisof precursor cells for osteogenic and hematopoietic tissues. Transplantation,1968,6(2):230-247.
|
|
|
| [4] |
Lazarus H M,Haynesworth S E,Gerson S L,et al. Ex vivo expansion and subsequent infusion of human bone marrow-derivedstromal progenitor cells (mesenchymal progenitor cells):implications fortherapeutic use. Bone Marrow Transplant,1995,16(4):557-564.
|
|
|
| [5] |
Pittenger M F, Mackay A M, Beck S C, et al. Multilineage potential of adult human mesenchymal stem cells. Science,1999,284(5411):143-147.
|
|
|
| [6] |
Dominici M, Le Blanc K,Mueller I,et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy,2006,8(4):315-317.
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
